Berlin - September 9, 2008 - MagForce Nanotechnologies AG will be presenting at this year’s UBS Global Life Sciences Conference in New York City. Dr. Uwe Maschek, CEO of MagForce Nanotechnologies, will provide an investor overview of the company and discuss the current status of its Nano-Cancer® therapy. The presentation will take place at the Grand Hyatt New York on September 25, 2008, starting at 11:00 a.m.
The annual UBS Global Life Sciences Conference is one of the world’s largest investor events within the pharmaceutical, medical technology and biotechnology sector, with more than 350 companies introducing their latest products and most promising research and development efforts to institutional investors.
Two days prior to this conference, on September 23 starting at 11:30 a.m., Dr. Maschek will deliver a company presentation at AdvaMed 2008 in Washington, D.C. AdvaMed is the annual conference of the Advanced Medical Technology Association, the U.S. industry association for medical technology.
About MagForce Nanotechnologies AG:
MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnology-based cancer treatment. Its patented therapy allows the targeted destruction of tumors using magnetic nanoparticles. MagForce’s nanotechnology represents a revolutionary approach to the future successful treatment of solid tumors.
About Nanostart:
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
